AgomAb Therapeutics (NASDAQ:AGMB) Stock Rating Upgraded by Zacks Research

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price objective for the company. Finally, Leerink Partners started coverage on AgomAb Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Trading Down 3.2%

NASDAQ AGMB opened at $14.21 on Wednesday. AgomAb Therapeutics has a fifty-two week low of $12.66 and a fifty-two week high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.